Dharmendra Kashyap
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dharmendra Kashyap has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amit Prasad
School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Mandi, India
1 shared publication - Budhadev Baral
Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Simrol, Indore, India
1 shared publication - Hamendra Singh Parmar
School of Biotechnology, Devi Ahilya Vishwavidyalaya, Khandwa Road, Indore, Madhya Pradesh, 452001, India
1 shared publication - Hem Chandra Jha
Infection Bioengineering Group, Mehta Family School of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Simrol, Indore, India
1 shared publication - Mrutyunjaya Panda
Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion 70013 Crete, Greece; Department of Medicine, University of Verona, Verona 37134, Italy; Faculty of Pharmacy, University of Lisbon, Lisbon 1649-003, Portugal
1 shared publication - Nidhi Varshney
Indian Institute of Technology Indore
1 shared publication
Latest Publications
- Open Access
Outer Membrane Vesicles: An Emerging Vaccine Platform
Vaccine adjuvants are substances that improve the immune capacity of a recombinant vaccine to a great extent and have been in use since the early 1900s; they are primarily short-lived and initiate antigen activity, mainly an inflammatory response. With the developing technologies and innovation, early options such as alum were modified, yet the inorganic nature of major vaccine adjuvants caused several side effects. Outer membrane vesicles, which respond to the stressed environment, are small nano-sized particles secreted by gram-negative bacteria. The secretory nature of OMV gives us many benefits in terms of infection bioengineering. This article aims to provide a detailed overview of bacteria’s outer membrane vesicles (OMV) and their potential usage as adjuvants in making OMV-based vaccines. The OMV adjuvant-based vaccines can be a great benefactor, and there are ongoing trials for formulating OMV adjuvant-based vaccines for SARS-CoV-2. This study emphasizes engineering the OMVs to develop better versions for safety purposes. This article will also provide a gist about the advantages and disadvantages of such vaccines, along with other aspects.
Open AccessOuter Membrane Vesicles: An Emerging Vaccine Platform
Vaccine adjuvants are substances that improve the immune capacity of a recombinant vaccine to a great extent and have been in use since the early 1900s; they are primarily short-lived and initiate antigen activity, mainly an inflammatory response. With the developing technologies and innovation, early options such as alum were modified, yet the inorganic nature of major vaccine adjuvants caused several side effects. Outer membrane vesicles, which respond to the stressed environment, are small nano-sized particles secreted by gram-negative bacteria. The secretory nature of OMV gives us many benefits in terms of infection bioengineering. This article aims to provide a detailed overview of bacteria’s outer membrane vesicles (OMV) and their potential usage as adjuvants in making OMV-based vaccines. The OMV adjuvant-based vaccines can be a great benefactor, and there are ongoing trials for formulating OMV adjuvant-based vaccines for SARS-CoV-2. This study emphasizes engineering the OMVs to develop better versions for safety purposes. This article will also provide a gist about the advantages and disadvantages of such vaccines, along with other aspects.